98%
921
2 minutes
20
As one of the most common neuropathic disorders, neuropathic pain often has a negative impact on patients with persistent pain, mood disorders and sleep disturbances. Currently, neuropathic pain is not treated with any specific drug, instead, drugs for other diseases are used as replacements in clinics, but most have adverse effects. In recent years, the role of spinal cord microglia in the pathogenesis of neuropathic pain has been widely recognized, and they are being explored as potential therapeutic targets. Spinal microglia are known to be involved in the pathogenic mechanisms of neuropathic pain through purine signaling, fractalkine signaling, and p38 MAPK signaling. Exercise is a safe and effective treatment, and numerous studies have demonstrated its effectiveness in improving neurological symptoms. Nevertheless, it remains unclear what the exact molecular mechanism is. This review summarized the specific molecular mechanisms of exercise in alleviating neuropathic pain by mediating the activity of spinal microglia and maintaining the phenotypic homeostasis of spinal microglia through purine signaling, fractalkine signaling and p38 MAPK signaling. In addition, it has been proposed that different intensities and types of exercise affect the regulation of the above-mentioned signaling pathways differently, providing a theoretical basis for the improvement of neuropathic pain through exercise.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10776684 | PMC |
http://dx.doi.org/10.1007/s11064-023-04025-4 | DOI Listing |
Pharmacoecon Open
September 2025
Department of Pharmacy, The Second Affiliated Hospital of Army Medical University, No.83 Xinqiao Central Street, Shapingba District, Chongqing, 400037, China.
Objective: Two vaccines against herpes zoster (HZ) are currently authorized for use in China: the adjuvanted recombinant zoster vaccine (RZV) and live-attenuated Zoster Vaccine Live (ZVL). The significant disparities in prices and efficacy between the two vaccines necessitate an evaluation of their relative value in order to make an informed choice. This study aimed to evaluate the comparative cost effectiveness of RZV, ZVL, and no vaccination for older adults at different ages from the societal perspective.
View Article and Find Full Text PDFActa Neurochir (Wien)
September 2025
Department of Neurosurgery, Kurume University School of Medicine 67, Asahimachi Kurume City, Fukuoka, 830-0011, Japan.
We report a 64-year-old woman who developed symptomatic vasospasm on postoperative day 7 after clipping of an unruptured right middle cerebral artery (MCA) aneurysm. Imaging revealed right MCA vasospasm, which resolved with oral antiplatelets and intravenous vasodilators. She was discharged without neurological deficits.
View Article and Find Full Text PDFClin Infect Dis
September 2025
Epidemiology Informatics, Centre for Health Analytics, Melbourne Children's Campus, Parkville, Victoria, Australia.
Background: Following the introduction of a funded recombinant shingles (RZV, Shingrix®) vaccination program in ≥65 years in Australia, clinician reports of shingles presentations shortly after vaccination emerged. We investigated whether there was an increase in shingles risk immediately post RZV vaccination in South-eastern Australia.
Methods: Two independent datasets- a general practice dataset and a statewide linked dataset- were analysed separately using self-controlled case series analyses (SCCS) with 21-days post-vaccination as the risk window.
Pain Manag
September 2025
Serviço de Reabilitação de Adultos 3, Centro de Medicina de Reabilitação de Alcoitão, Alcabideche, Portugal.
Pudendal neuropathy is a cause of pelvic pain, specifically pudendal neuralgia. The pudendal nerve is related to sensory, motor, and autonomic functions. We present the case of a 41-year-old man who suffered from chronic pelvic pain.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Department of Neurosurgery, Peking University People's Hospital, Beijing, China.
Background: Despite a surge in neuropathic pain (NP) biomarker research over the past 2 decades, the translation of discoveries into clinical practice remains slow. To understand this translational gap, we conducted a comprehensive bibliometric analysis to map the field's evolution, intellectual structure, and strategic challenges.
Methods: We conducted a bibliometric analysis of NP biomarker-related publications from 2004 to 2024 using the Web of Science Core Collection (WoSCC) database.